SP Backs HepaTx in Licensing Deal with Mayo Clinic for Liver Therapy

​Stem cell therapy for liver damage is an emerging field in regenerative medicine, with treatments facing varied legal statuses due to differing regulations and ethical concerns. HepaTx, supported by SP Investment Fund LLC, is advancing the development of off-the-shelf stem cell therapeutics for liver disease and related disorders requiring regenerative treatment.

Late-stage liver disease treatment often struggles with organ shortages, high costs, and the risk of tissue rejection. HepaTx, backed by the SP Investment Fund, signed a license agreement with the Mayo Clinic to use stem cell technologies in clinical trials to address these issues.

This partnership aims to advance liver disease treatments by focusing initially on alcohol-related hepatitis, a prevalent health issue. Under the agreement, HepaTx will leverage Mayo Clinic's clinical research expertise to transition its technology from preclinical stages to human trials. HepaTx's approach uses stem cells derived from adipose tissue to target acute and chronic liver diseases.

This collaboration aims to accelerate the introduction of HepaTx's cell therapy into clinical trials, fostering innovative solutions that could improve patient outcomes and potentially transform liver disease treatment. With Mayo Clinic's expertise in liver disease and regenerative medicine, HepaTx CEO Eric Schuur emphasized the team's commitment to working with Mayo Clinic's experienced researchers to deliver these therapies to patients.

SP Investment Fund

Shop